GlassScriptPhysician profile
Ann C Linares
NPI 1790892065
$5,370.03
in general payments reported to CMS, 2019-2025
49 companies · $773 in 2025
The $773 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $460 · 2021: $872 · 2022: $1,036 · 2023: $1,034 · 2024: $776 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,559 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,558.56 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,238.74 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,140.21 | 2019-2025 | |
| Lilly USA, LLC | $242.26 | 2019-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $237.37 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $203.81 | 2019-2025 | |
| Edwards Lifesciences Corporation | $189.89 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $185.61 | 2022-2025 | |
| Eisai INC. | $153.47 | 2020-2022 | |
| Amgen INC. | $146.09 | 2019-2025 | Evenity, Prolia |
| Pfizer INC. | $132.13 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $106.55 | 2019-2022 | |
| Gilead Sciences, INC. | $90.64 | 2020-2024 | |
| Glaxosmithkline, LLC. | $88.69 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $81.63 | 2021-2025 | Trintellix |
| Astellas Pharma US INC | $79.35 | 2023-2025 | Veozah, Myrbetriq |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Linares listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.